Publications

Tarantino P, Rugo HS, Curigliano G, O'Shaughnessy JA, Janni W, Jhaveri K, Mouabbi J, Brufsky A, Hamilton E, O'Regan R, Santarsiero L, Akdere M, Ye F, Scotchmer A, Graff SL. Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2- early breast cancer: a United States Electronic Health Records database analysis. ESMO open. 2025. PMID: 40516131

Madhuri Chengappa, Thejaswi K Poonacha, Nikitha Vobugari, Go Nishikawa, Saya Jacob, Samantha Fisch, Carolyn Face, Alexis LeVee, Nikita V. Baclig, Andrew Soliman, Laura Huppert, Laura Quintal, Michelle Melisko, Melanie Majure, Jo Chien, Joanne Mortimer, Kelly McCann, Hope S. Rugo, Dame Idossa, Anne Blaes. Abstract P1-12-04: Correlation between Immune-Related Adverse Events (irAE) and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Immune Checkpoint Inhibitors (ICI): a multi-institutional study. Clinical Cancer Research. 2025. PMID:

Laura A. Huppert, Kelsey Kuwahara, Maggie Zhou, Mia Salans, Samantha Fisch, Jo Chien, Melanie Majure, Hope Rugo, Lauren Boreta, Steve E. Braunstein, Ramin A. Morshed, Harish N. Vasudevan, Michelle E. Melisko. Abstract P5-10-01: Demographic, Clinical Characteristics, and Overall Survival of Patients with Metastatic Breast Cancer and Brain Metastases: A Single Center Retrospective Cohort Study. Clinical Cancer Research. 2025. PMID:

Zeidner JF, Lin TL, Welkie RL, Curran E, Koenig K, Stock W, Madanat YF, Swords R, Baer MR, Blum W, Stein EM, Olin RL, Schiller G, Nichols A, Odenike O, Traer E, Lachowiez C, Duong VH, Hochman MJ, Cai SF, Smith C, Stefanos M, Martycz M, Huang Y, Rosenberg L, Marcus S, Chen TL, Yocum AO, Druker BJ, Levine RL, Borate U, Byrd JC, Mims AS. Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40504618

Stevers NO, Kim S, Yuan JB, Barger CJ, Hong C, Lenzo O, McKinney AM, Wu SH, Lee YJ, Kwok DW, Suwala AK, Appin CL, Gordan JD, Molinaro AM, Song JS, Costello JF. The immortality mechanism of TERT promoter mutant cancers is self-reinforcing and reversible. Molecular cell. 2025. PMID: 40513567

Tien JC, Zhai Y, Wu R, Zhang Y, Chang Y, Cheng Y, Todd AJ, Wheeler CE, Li S, Mannan R, Cheng C, Magnuson B, Cruz G, Cao Y, Mahapatra S, Stolfi C, Cao X, Su F, Wang R, Yang J, Zhou L, Qiao Y, Xiao L, Cieslik M, Wang X, Wang Z, Chou J, Fearon ER, Ding K, Cho KR, Chinnaiyan AM. Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 2025. PMID: 40504161

Zhou P, Mansukhani MM, Yeh R, Lu J, Xia H, Koganti L, Pang J, Toskic D, Scalia S, Ma X, Lee LX, Wong SW, Chung A, Tuchman SA, Fogaren T, Coady Lyons N, Varga C, Lentzsch S, Comenzo RL. Screening for Systemic Light-Chain Amyloidosis in Patients Over 60 with λ Monoclonal Gammopathies. Journal of clinical medicine. 2025. PMID: 40565890

Epstein L, Weiner AC, Verma A, Saedi M, Carnevale J, Marson A, Engelhardt BE. Live-cell analyses with unsegmented images to study cancer cell response to modified T cell therapy. bioRxiv : the preprint server for biology. 2025. PMID: 40502136

Rugo HS, Xu B, Dasgupta A, Kaushik A, Verret W, Singh B. A Meta-Analysis of Patient-Reported Outcomes of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Previously Treated HR+/HER- mBC Using Two Phase 3 (TROPiCS-02 and EVER-132-002) Trials. Cancers. 2025. PMID: 40507364

Miller J, Cuby J, Hall SM, Stitzer M, Kushel M, Appiah D, Vijayaraghavan M. Corrigendum to "Tobacco use behaviors and views on engaging in clinical trials for tobacco cessation among individuals who experience homelessness" [Contemporary Clinic. Trials Commun. 32 (2023) 101094]. Contemporary Clinical Trials Communications. 2025. PMID: 40727927

Beckermann KE, Shah NJ, Campbell MT, Haas NB, Nelson A, Ornstein MC, Mao S, Keshava-Prasad HS, Hammers H, Gao X, Gourdin T, George S, Hoimes CJ, Hussain A, Jonasch E, Rini BI, Voss MH. Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma. The oncologist. 2025. PMID: 40549043

Liao N, Li C, Gradishar WJ, Klimberg VS, Roshal JA, Yuan T, Agarwala SS, Valero VK, Swain SM, Margenthaler JA, Rubio IT, Hurvitz SA, Geyer CE, Lin NU, Rugo HS, Zhang G, Liu N, Balch CM. Accuracy and Reproducibility of ChatGPT Responses to Breast Cancer Tumor Board Patients. JCO clinical cancer informatics. 2025. PMID: 40466030

Naughton MJ, Zahrieh DM, Gnant M, Zdenkowski N, Lemieux J, Mao JJ, Bjelic-Radisic V, Shinn E, Balic M, Thomssen C, Meisel JL, Ruiz GM, Loibl S, Isaacs C, Cameron D, Henao-Carrasco FM, Goetz MP, Singer CF, Werutsky G, Rugo HS, Vetter M, Tseng LM, Miller K, Fitzal F, Gil Gil JM, Park H, Linderholm B, Bajetta E, Dayao Z, Prat A, Ehrhardt K, Metzger O, Arahmani A, Law EH, Partridge AH, Carey LA, Zoroufy A, Dueck AC, O'Brien P, Hlauschek D, DeMichele A, Mayer EL. Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109). ESMO open. 2025. PMID: 40472660

Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, Deol A, Agha M, Berdeja JG, Lesokhin AM, Liegel JJ, Rossi A, Lieberman-Cribbin A, Usmani SZ, Dhakal B, Parekh S, Li H, Wang F, Montes de Oca R, Plaks V, Sun H, Banerjee A, Schecter JM, Lendvai N, Madduri D, Lengil T, Zhu J, Koneru M, Akram M, Patel N, Costa Filho O, Jakubowiak AJ, Voorhees PM. Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40459151

Soragni A, Knudsen ES, O'Connor TN, Tognon CE, Tyner JW, Gini B, Kim D, Bivona TG, Zang X, Witkiewicz AK, Goodrich DW, Jiang D, Gammon ST, Willey CD, Boutros PC, Sandulache VC, Osman AA, Myers JN, Mehla K, Singh PK, Chan KS, Gao H, Marathe H, National Cancer Institute (NCI) Acquired Resistance to Therapy Network (ARTNet). Acquired resistance in cancer: towards targeted therapeutic strategies. Nature reviews. Cancer. 2025. PMID: 40461793

Parihar AS, Pant N, Heidari P, Fong L, Iravani A. Approaches to Imaging Immune Activation Using PET. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2025. PMID: 40306967

Jonas BA, Fisch SC, Curtin PT, Schiller GJ, Jeyakumar D, Tzachanis D, Bejar R, Qi L, Wieduwilt MJ, Tuscano JM, Damon L, Logan AC, University of California Hematologic Malignancies Consortium. A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503). Leukemia Research. 2025. PMID: 40479857

He J, Tsuboi M, Weder W, Chen KN, Hochmair MJ, Shih JY, Lee SY, Lee KY, Nhung NV, Saeteng S, Liu L, Xing L, Gia NH, Murakami S, Han Y, Saavedra MP, Yoon SH, Teixeira CHA, Escriu C, Martinez-Marti A, Blakely CM, Yatabe Y, Dacic S, Rukazenkov Y, Huang X, Dayal A, Chaft JE, NeoADAURA Investigators. Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40454705

Kennedy VE, Roy R, Peretz CAC, Koh A, Tran E, Smith CC, Olshen AB. SNACS: a tool for demultiplexing single-cell DNA sequencing data. Bioinformatics (Oxford, England). 2025. PMID: 40471703

García-Estévez L, Bardia A, Rugo HS, Carey LA, Diéras VC, Loibl S, Piccart M, Gianni L, Kalinsky K, O'Shaughnessy J, Hurvitz SA, Harting E, Valdez T, Phan S, Lai C, Cortés J. The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study. ESMO open. 2025. PMID: 40460679